Spyre Therapeutics (NASDAQ:SYRE) Shares Up 6.3% After Analyst Upgrade

Spyre Therapeutics, Inc. (NASDAQ:SYRE)’s share price traded up 6.3% during trading on Friday after Wells Fargo & Company raised their price target on the stock from $40.00 to $50.00. Wells Fargo & Company currently has an overweight rating on the stock. Spyre Therapeutics traded as high as $39.69 and last traded at $40.2020. 39,453 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 624,201 shares. The stock had previously closed at $37.81.

SYRE has been the topic of several other research reports. JonesTrading upgraded Spyre Therapeutics from a “hold” rating to a “buy” rating and set a $64.00 target price on the stock in a research note on Monday, December 1st. BTIG Research reiterated a “buy” rating and issued a $70.00 price objective on shares of Spyre Therapeutics in a report on Friday. Mizuho raised shares of Spyre Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Spyre Therapeutics in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Spyre Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $53.44.

Insider Buying and Selling at Spyre Therapeutics

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $32.80, for a total value of $492,000.00. Following the completion of the sale, the chief executive officer owned 657,540 shares in the company, valued at $21,567,312. This trade represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 45,000 shares of company stock valued at $1,387,500 over the last three months. 15.43% of the stock is currently owned by company insiders.

Key Stories Impacting Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and kept a $70 price target (roughly +62% upside vs. current levels), signaling strong buy-side conviction from a sell-side firm. BTIG Reaffirms Buy, $70 PT
• Positive Sentiment: Wells Fargo raised its price target to $50 and assigned an “overweight” rating, providing additional analyst support that likely helped lift the stock. Wells Fargo Raises PT to $50
• Positive Sentiment: Spyre reported a strong cash position — $757M in cash, equivalents and marketable securities as of 12/31/25 — and said that runway is expected into H2 2028, reducing near-term financing risk. The company also completed an offering in Oct 2025 and added a Chief Commercial Officer. Q4 & Corporate Update
• Positive Sentiment: Management reiterated an aggressive 2026 clinical cadence: up to six proof-of-concept readouts across the SKYLINE and SKYWAY Phase 2 programs (including Part A readouts starting in Q2 and multiple basket-study sub-readouts later in the year), which creates several near-term clinical catalysts. Clinical Readouts and Timeline
• Neutral Sentiment: Spyre announced presentations at the 21st ECCO Congress showcasing SPY003’s differentiated profile and preclinical combo data — supportive from a scientific/visibility standpoint but not an immediate financial catalyst. ECCO Presentations
• Negative Sentiment: Spyre missed the quarterly EPS consensus (reported -$0.70 vs. est. -$0.66), a modest miss that may temper sentiment for investors focused on near-term financials. Earnings Release

Hedge Funds Weigh In On Spyre Therapeutics

Several large investors have recently modified their holdings of SYRE. Invesco Ltd. boosted its holdings in shares of Spyre Therapeutics by 197.7% during the 4th quarter. Invesco Ltd. now owns 150,934 shares of the company’s stock worth $4,945,000 after buying an additional 100,232 shares during the period. VARCOV Co. acquired a new stake in Spyre Therapeutics during the fourth quarter worth approximately $262,000. Virtus Investment Advisers LLC lifted its position in Spyre Therapeutics by 23.2% during the fourth quarter. Virtus Investment Advisers LLC now owns 7,913 shares of the company’s stock worth $259,000 after acquiring an additional 1,488 shares during the last quarter. Susquehanna Portfolio Strategies LLC boosted its holdings in shares of Spyre Therapeutics by 144.3% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 53,101 shares of the company’s stock worth $1,740,000 after acquiring an additional 31,362 shares during the period. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Spyre Therapeutics in the fourth quarter valued at approximately $332,000. 80.39% of the stock is owned by institutional investors.

Spyre Therapeutics Price Performance

The company has a market cap of $3.35 billion, a price-to-earnings ratio of -20.77 and a beta of 3.15. The firm has a 50-day moving average price of $33.40 and a 200 day moving average price of $25.29.

Spyre Therapeutics (NASDAQ:SYRE) last posted its earnings results on Thursday, February 26th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). On average, equities analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.